NeuroPace (NPCE)
(Delayed Data from NSDQ)
$13.39 USD
+0.40 (3.08%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $13.38 -0.01 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NPCE 13.39 +0.40(3.08%)
Will NPCE be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NPCE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NPCE
Thermo Fisher Scientific (TMO) Tops Q1 Earnings and Revenue Estimates
RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates
NPCE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alphatec (ATEC) Reports Q3 Loss, Tops Revenue Estimates
Accuray (ARAY) Reports Q1 Loss, Misses Revenue Estimates
Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Lags Revenue Estimates
Other News for NPCE
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
‘Time to Hit Buy,’ Says Wells Fargo About These 2 Stocks
NeuroPace to Present at the Needham 23rd Annual Healthcare Conference
Wells Fargo upgrades NeuroPace to Overweight, raises price target to $20
Wells Fargo gets more bullish on NeuroPace, upgrades shares